A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease

Trial Profile

A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Ferumoxytol (Primary) ; Ferrous fumarate
  • Indications Iron deficiency anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors AMAG Pharmaceuticals
  • Most Recent Events

    • 19 Sep 2016 Status changed from active, no longer recruiting to discontinued as several factors contributed to significant challenges in enrollment and led the Sponsor to discontinue the AMAG-FER-CKD-251 study as designed.
    • 15 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record..
    • 15 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top